Announcements
Sidley Represents Respira in Its Option to Be Acquired by Gossamer Bio
September 30, 2025
Sidley represented Respira Therapeutics, Inc., a Samsara BioCapital portfolio company, in its agreement granting an option to Gossamer Bio, Inc. (Nasdaq: GOSS) to acquire the company. Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed therapy for use in pulmonary hypertension.
The Sidley team was led by partner Jason Kropp and counsel Rebecca Nauta (Emerging Companies and Venture Capital), and included Dr. Christian Brause and Andy Lau (Tax); Nicholas Frey (Employee Benefits and Executive Compensation); Lauren Grau (Technology and Life Sciences Transactions); and Ethan McMahon and Margalit Zimand (M&A).
連絡先
得意分野
Suggested News & Insights
Sidley Represents Aquestive Therapeutics in Exclusive U.S. Licensing Agreement With Eton PharmaceuticalsOctober 16, 2026Sidley Represents Nous Research in US$90 Million Series B FinancingOctober 12, 2026Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE BiosciencesOctober 7, 2026Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With SomniveraSeptember 30, 2026Sidley Represents Bluevine in Its US$340 Million Acquisition by Valley National BankSeptember 28, 2026Sidley Represents Star51 Capital in Its Investment in UltraSight’s US$24 Million FinancingSeptember 25, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory